6月3日-6日，2019美国生物技术大会暨展览会（2019 Biotechnology Innovation Organization International Convention）在美国宾夕法尼亚州费城举行，复宏汉霖以及复星医药集团亮相此次大会。
来访者对复宏汉霖产品管线留下深刻印象
此次大会共吸引了逾1800位参展商以及17300多位全球行业领导者和顶级研究学者，他们在大会上与来自全球的生物制药公司和医药公司共同探索合作共赢的潜在机遇。短短几天，复宏汉霖累计参与了190多场会面，同来自全球的合作商探讨了在生物制品治疗、技术平台、肿瘤免疫联合疗法等方面建立良好合作关系的可能性。不少合作商对复宏汉霖的产品管线、特别是首个获批上市的中国国产生物类似药汉利康®留下了深刻印象。
质高价优的治疗方案受人瞩目
复宏汉霖展台吸引了多位访问者/组织机构前来拜访，这其中不乏全球新药研发组织和知名临床研究机构。复宏汉霖联合创始人、首席科学官姜伟东博士表示：“当谈及质高价优的治疗方案时，没有人不会对之产生兴趣。我们之间总能产生思维的碰撞，继而探索更多持续的创新。”
当被问及复宏汉霖对将在圣地亚哥举行的2020美国生物技术大会暨展览会有何期待时，复宏汉霖商务拓展副总裁曹平女士表示，通过此次2019美国生物技术大会暨展览会，复宏汉霖已与诸多美国和欧洲地区的潜在合作商建立了良好联系，相信2020美国生物技术大会暨展览会也会为复宏汉霖继续探索全球合作关系提供更多机会，同时也期待2020美国生物技术大会暨展览会能回归加利福尼亚州，复宏汉霖的美国研发中心也坐落于此。
复宏汉霖积极推动全球布局
近年来，复宏汉霖积极推动全球布局。研发方面，自2010年公司成立以来，复宏汉霖以全球联动、整合创新为产品开发理念，在中国上海、台北和美国加州均设有研发实验室，具备了两岸三地技术互补的突出优势。产品方面，其另一重磅产品HLX02（注射用曲妥珠单抗）已相继在中国大陆、乌克兰、欧盟波兰和菲律宾全面启动国际多中心3期临床试验，成为国内首个开展国际多中心3期临床研究的生物类似药，现已提交上市申请。凭借领先的国际质量标准，复宏汉霖已与一些全球领先的医药公司达成战略商业化合作，以透过合作伙伴既有的能力和资源迅速占有海外市场份额。复宏汉霖与海外Accord、Cipla、Biosidus及Jacobson等公司签订了商业合作协议，对外授权覆盖全球82个国家和地区。
未来，复宏汉霖也会持续探索更多国际化合作可能，在国际化的道路上继续秉“质”前行，以优质生物药，造福全球病患！
关于美国生物技术大会暨展览会
美国生物技术大会暨展览会(BIO International Convention)是全球最大的生物技术行业盛会，聚集了来自全球的业内领先生物制药公司、投资商及合作商，并有诸多合作活动在大会期间举行。大会由美国生物技术创新组织机构(Biotechnology Innovation Organization，以下简称“BIO”) 主办，是代表生物技术公司、学术机构和相关机构的全球最大生物技术行业协会，其成员覆盖美国和其他30个国家。BIO致力于为生物技术行业提供更多行业交流、合作机遇机会。
关于复宏汉霖
上海复宏汉霖生物技术股份有限公司为一家中国领先的生物制药公司，致力于为全球患者提供质高价优的创新生物药。自2010年成立以来，公司在中国上海、台北和美国加州均设有研发中心，已经建立并持续拓展全面的生物类似药及生物创新药产品管线，产品覆盖肿瘤、自身免疫性疾病等领域。
截至目前，复宏汉霖13个产品、2个联合治疗方案已完成23项适应症的临床试验申请，累计获得全球范围内29个临床试验许可（中国大陆19个，中国台湾3个，美国3个，欧盟、澳大利亚、乌克兰和菲律宾各1个）。其中，公司首款重磅产品汉利康®（利妥昔单抗注射液）已获国家药监局新药上市注册批准，成为中国首个获批上市的生物类似药。HLX03（阿达木单抗注射液）于2019年1月获国家药监局新药上市申请受理，现已纳入优先审评程序。HLX02（注射用曲妥珠单抗）相继在中国大陆、乌克兰、欧盟波兰和菲律宾全面启动国际多中心3期临床试验，成为国内首个开展国际多中心3期临床研究的生物类似药，于2019年4月获国家药监局新药上市申请受理。
Henlius Attends BIO 2019
This past week, the Biotechnology Innovation Organization’s 2019 (BIO-2019) International Convention attracted more than 17,300 top biotech innovators, researchers and visionaries across the globe at the Pennsylvania Convention Center in Philadelphia. As one of the 1,800 exhibitors, Shanghai Henlius Biotech, Inc. (Henlius), along with Fosun Pharma (the parent company of Henlius), had an opportunity to connect with many biotechnology and pharmaceutical companies’ leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships at the convention. Through back-to-back scheduled meetings , Henlius ended with more than 190 meetings with national and international partners and multiple possible leads for in-licensing, research collaboration or commercial right out-licensing conducting at the Henlius’ booth over the course of three-day exhibition. These discussions were primarily focused on advancing new approaches to science, including therapeutic biologics, technology platforms, and immuno-oncology combinations, and building robust partnerships to accelerate innovation. A large majority of these potential future partners has confirmed their interest in continuing an in-depth conversion with Henlius after BIO-2019.
Since the first rituximab biosimilar being approved by China National Medical Products Administration (NMPA) on February 22, 2019, Henlius has been recognized as a rising star by many companies worldwide. Attendees who had previously not familiar with Henlius were quite impressed by its pipeline in both biosimilar and bio-innovative antibodies and expressed interests in collaborating with Henlius in a variety of ways. Dr. Weidong Jiang, Chief Scientific Officer and Co-Founder at Henlius, stated that “there is no shortage of excitement, innovation or ideas, particularly when it comes to affordable and effective treatments”. Jiang agreed, noting that Henlius had a daily flow of 40+ interested visitors and organizations ranging from potential global drug developers to branding Clinical Research Organizations dropping by at the booth.
When Ms. Ping Cao, Vice President of Business Development at Henlius, was asked by the BIO organizer “what will be the objective for Henlius at the next BIO-2020 in San Diego?” Ping shared some words of excitement: with many productive meetings accomplished at BIO-2019, Henlius has made connections with a handful of potential collaborations and partnerships especially in the USA and Europe. Henlius purses every opportunity to help patients, caregivers, regulators and the industry as working together to impact affordability of effective treatments. BIO-2020 will be a great opportunity for Henlius to continue connecting with global partners. Henlius looks forward to welcoming the BIO-2020 back to California where one of its R&D facilities is located in the Bay Area.
Henlius pressed forward with global footprint in recent years. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process. On the product side, HLX02 (trastuzumab injection), one of the major products, is the first biosimilar developed in China to enter a multi-jurisdictional Phase 3 clinical trial in China, Poland, Ukraine and the Philippines. HLX02 received a New Drug Application (NDA) acceptance from the NMPA in April, 2019. Moreover, with global quality standard, Henlius has proven track record of initiating strategic commercialisation collaborations with global leading pharmaceutical companies, which will enable Henlius to expeditiously capture market share through the established capabilities and partner resources. To this end, Henlius has entered into license and commercialisation agreements with multiple partners, including Accord, Cipla, Biosidus and Jacobson Medical. Henlius has entered into agreements for the licensing and commercialisation in over 82 jurisdictions and regions.